PMID- 20109612
OWN - NLM
STAT- MEDLINE
DCOM- 20100401
LR  - 20211203
IS  - 1532-8686 (Electronic)
IS  - 0037-1963 (Linking)
VI  - 47
IP  - 1
DP  - 2010 Jan
TI  - Transplant outcomes in acute leukemia. II.
PG  - 51-8
LID - 10.1053/j.seminhematol.2009.10.005 [doi]
AB  - Currently, it is possible to find a hematopoietic stem cell (HSC) donor for 
      virtually all patients with acute leukemia who have an indication to receive an 
      allogeneic hematopoietic stem cell transplant (HSCT) and lack a human leukocyte 
      antigen (HLA)-identical sibling or a well-matched HLA unrelated donor (URD). 
      According to the ethnicity of the patients and the donor registry, approximately 
      25% to 60% of patients will not find an 8/8 HLA-matched unrelated donor. Other 
      alternative donors, such as HLA-mismatched related donor or unrelated donor 
      umbilical cord blood (UCB), have emerged to solve the lack of a sibling or 
      well-matched URD. In the haploidentical HSCT setting, new techniques of T-cell 
      depletion, new approaches using combinations of immunosuppressive drugs or 
      different conditioning regimens, and developments on immunotherapy have focused 
      attention on this option. Therefore, any physician has to carefully evaluate, for 
      each patient in need of an allograft, all of the possible alternatives in order 
      to choose the best HSC donor, taking into account type of disease to be 
      transplanted, urgency of transplantation, donor characteristics, and center 
      experience. This review evaluates the current status of haploidentical HSCT in 
      acute leukemia, its advantages and remaining limitations compared to other stem 
      cell sources, and how these data may be used in the development of donor 
      selection algorithms.
CI  - (c) 2010 Elsevier Inc. All rights reserved.
FAU - Hough, Rachael
AU  - Hough R
AD  - University College London, London, United Kingdom. Rachael.hough@uclh.nhs.uk
FAU - Rocha, Vanderson
AU  - Rocha V
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Hematol
JT  - Seminars in hematology
JID - 0404514
SB  - IM
MH  - Algorithms
MH  - Blood Donors/*supply & distribution
MH  - *Cord Blood Stem Cell Transplantation/adverse effects/mortality
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects/mortality
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunosuppression Therapy
MH  - Leukemia/mortality/*surgery
MH  - *Patient Selection
MH  - Time Factors
MH  - Transplantation, Homologous
MH  - Treatment Outcome
RF  - 46
EDAT- 2010/01/30 06:00
MHDA- 2010/04/02 06:00
CRDT- 2010/01/30 06:00
PHST- 2010/01/30 06:00 [entrez]
PHST- 2010/01/30 06:00 [pubmed]
PHST- 2010/04/02 06:00 [medline]
AID - S0037-1963(09)00136-X [pii]
AID - 10.1053/j.seminhematol.2009.10.005 [doi]
PST - ppublish
SO  - Semin Hematol. 2010 Jan;47(1):51-8. doi: 10.1053/j.seminhematol.2009.10.005.